EC Number   |
Application |
Reference |
|---|
   1.14.14.25 | drug development |
generation of imidazo[1,2-a]pyridine analogues that effectively inhibit cholesterol 24-hydroxylase (CYP46A1). They can be used for prophylactic treatment of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease |
736072 |
| 1.14.14.25 | medicine |
abnormal expression of cholesterol 24S-hydroxylase in astrocytes in Alzheimer's disease, which may limit the usefulness of the plasma marker 24S-hydroxycholesterol in this specific disease |
705920 |
| 1.14.14.25 | medicine |
CYP46A1 affects the pathophysiology of AD and provides insight into how polymorphisms in the CYP46A1 gene might influence the pathophysiology of this prevalent disease |
659374 |
| 1.14.14.25 | medicine |
genotyping of CYP46A1 gene polymorphisms (associated with the risk of Alzheimer's disease in Chinese) |
698342 |
| 1.14.14.25 | medicine |
restoring CYP46A1 activity in the striatum promises a therapeutic approach in Huntington's disease |
735877 |
| 1.14.14.25 | medicine |
the enzyme is a potential target for Alzheimers disease as it can be activated pharmacologically by some of the marketed drugs as exemplified by efavirenz (EFV), the anti-HIV medication |
736502 |
